📊 IONS Key Takeaways
Is Ionis Pharmaceuticals Inc. (IONS) a Good Investment?
Ionis Pharmaceuticals exhibits severe fundamental deterioration with massive operating losses (-$381.7M) despite 33.8% revenue growth, indicating unprofitable growth driven by R&D-heavy operations rather than sustainable business improvements. The company is burning significant cash (-$320M free cash flow) while carrying high leverage (3.71x debt/equity), raising concerns about long-term viability without major operational restructuring or successful late-stage pipeline commercialization.
Ionis shows solid top-line growth, but the quality of that growth is weak because it is paired with extremely negative operating margins, large net losses, and deeply negative free cash flow. The balance sheet still has meaningful liquidity, yet high leverage, negative interest coverage, and a thin equity base make the financial profile fragile if cash burn does not improve materially.
Why Buy Ionis Pharmaceuticals Inc. Stock? IONS Key Strengths
- Strong revenue growth of 33.8% year-over-year demonstrates market demand and commercialization progress
- Adequate liquidity position with $372.3M cash and 3.83x current ratio providing near-term operational runway
- Improved net income loss by 16.0% YoY suggesting operational leverage beginning to develop despite losses
- Revenue grew 33.8% year over year, indicating commercial or partnership momentum
- Current ratio of 3.83x and quick ratio of 3.81x suggest near-term liquidity is still solid
- Large asset base provides financial flexibility relative to current operating scale
IONS Stock Risks: Ionis Pharmaceuticals Inc. Investment Risks
- Massive operating losses of -$381.7M with negative operating margin of -187.7% indicating core business is deeply unprofitable
- Negative free cash flow of -$320M coupled with high debt burden of $1.8B creates urgent need for profitability transition or additional capital
- Deteriorating cash burn rate (-$268.6M operating cash outflow) with no clear path to profitability in near term, requiring successful commercialization of pipeline candidates
- Operating margin of -187.7% and net margin of -187.6% indicate an unsustainable profitability profile
- Free cash flow of -$320.03M and operating cash flow of -$268.58M show heavy ongoing cash burn
- Debt-to-equity of 3.71x with negative interest coverage and only $489.09M of equity creates significant balance-sheet risk
Key Metrics to Watch
- Operating margin trajectory - must show meaningful improvement toward 0% within 2-3 years
- Free cash flow burn rate - sustainability depends on reducing cash consumption or achieving revenue inflection
- Debt/Equity ratio and cash runway - critical to monitor given current leverage and burn rate
- Operating cash flow and free cash flow burn rate
- Debt load relative to equity and progress toward positive operating margin
Ionis Pharmaceuticals Inc. (IONS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.83x current ratio provides a solid financial cushion.
IONS Profit Margin, ROE & Profitability Analysis
IONS vs Healthcare Sector: How Ionis Pharmaceuticals Inc. Compares
How Ionis Pharmaceuticals Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Ionis Pharmaceuticals Inc. Stock Overvalued? IONS Valuation Analysis 2026
Based on fundamental analysis, Ionis Pharmaceuticals Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Ionis Pharmaceuticals Inc. Balance Sheet: IONS Debt, Cash & Liquidity
IONS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Ionis Pharmaceuticals Inc.'s revenue has declined by 16% over the 5-year period, indicating business contraction. The most recent EPS of $-2.56 indicates the company is currently unprofitable.
IONS Revenue Growth, EPS Growth & YoY Performance
IONS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $133.8M | -$128.6M | $-0.80 |
| Q2 2025 | $225.3M | -$23.4M | $-0.15 |
| Q1 2025 | $119.5M | -$142.8M | $-0.93 |
| Q3 2024 | $133.8M | -$140.5M | $-0.95 |
| Q2 2024 | $188.4M | -$66.3M | $-0.45 |
| Q1 2024 | $119.5M | -$124.3M | $-0.87 |
| Q3 2023 | $144.2M | -$47.0M | $-0.33 |
| Q2 2023 | $133.8M | -$85.3M | $-0.60 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Ionis Pharmaceuticals Inc. Dividends, Buybacks & Capital Allocation
IONS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Ionis Pharmaceuticals Inc. (CIK: 0000874015)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IONS
What is the AI rating for IONS?
Ionis Pharmaceuticals Inc. (IONS) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IONS's key strengths?
Claude: Strong revenue growth of 33.8% year-over-year demonstrates market demand and commercialization progress. Adequate liquidity position with $372.3M cash and 3.83x current ratio providing near-term operational runway. ChatGPT: Revenue grew 33.8% year over year, indicating commercial or partnership momentum. Current ratio of 3.83x and quick ratio of 3.81x suggest near-term liquidity is still solid.
What are the risks of investing in IONS?
Claude: Massive operating losses of -$381.7M with negative operating margin of -187.7% indicating core business is deeply unprofitable. Negative free cash flow of -$320M coupled with high debt burden of $1.8B creates urgent need for profitability transition or additional capital. ChatGPT: Operating margin of -187.7% and net margin of -187.6% indicate an unsustainable profitability profile. Free cash flow of -$320.03M and operating cash flow of -$268.58M show heavy ongoing cash burn.
What is IONS's revenue and growth?
Ionis Pharmaceuticals Inc. reported revenue of $203.3M.
Does IONS pay dividends?
Ionis Pharmaceuticals Inc. does not currently pay dividends.
Where can I find IONS SEC filings?
Official SEC filings for Ionis Pharmaceuticals Inc. (CIK: 0000874015) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IONS's EPS?
Ionis Pharmaceuticals Inc. has a diluted EPS of $-2.38.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IONS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Ionis Pharmaceuticals Inc. has a SELL rating with 84% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IONS stock overvalued or undervalued?
Valuation metrics for IONS: ROE of -78.0% (sector avg: 15%), net margin of -187.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IONS stock in 2026?
Our dual AI analysis gives Ionis Pharmaceuticals Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IONS's free cash flow?
Ionis Pharmaceuticals Inc.'s operating cash flow is $-268.6M, with capital expenditures of $51.4M. FCF margin is -157.4%.
How does IONS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -187.6% (avg: 12%), ROE -78.0% (avg: 15%), current ratio 3.83 (avg: 2).
Is Ionis Pharmaceuticals Inc. carrying too much debt?
IONS has a debt-to-equity ratio of 3.71x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 3.83 suggests adequate short-term liquidity.